ArticleMedicine2025
Analyzing the causal relationship between gut microbiotas, blood metabolites, and COVID-19 susceptibility: A Mendelian randomization study.
Article in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Gut microbiota and blood metabolites play crucial roles in the progression and outcomes of COVID-19, but the causal relationships and mechanisms remain unclear. Our aim is to use two-sample Mendelian randomization (MR) to explore the causal relationships between gut microbiota, COVID-19 susceptibility, and potential mediating blood metabolites. We utilized summary statistics from the largest genome-wide association studies (GWAS) to date on gut microbiota (n = 18,340), blood metabolites (n = 115,078), and COVID-19 susceptibility (cases n = 60,176 and controls n = 1310,725 from the COVID-19 Host Genetics Initiative meta-analysis). We conducted bidirectional MR analyses to explore the causal relationships between gut microbiota and COVID-19 susceptibility and performed two-step MR to identify potential mediating blood metabolites. Five analytical methods were used to assess two-sample causal relationships, with inverse variance weighted (IVW) being the primary method. Sensitivity analyses were also conducted to ensure the robustness of the main MR results. Using the IVW method, we found causal relationships between 3 types of gut microbiota and 34 blood metabolites with COVID-19 susceptibility. In the two-step MR, the non-oxidative branch of the Pentose phosphate pathway was shown to reduce Sebacate (C10-DC) levels, and the species Parabacteroides goldsteinii was negatively correlated with Acetoacetate levels. Sebacate (C10-DC) levels were negatively associated with COVID-19 susceptibility, while Acetoacetate levels were positively associated with COVID-19 susceptibility. Furthermore, these causal relationships remained significant after correcting for false discovery rates (all q-values < 0.05). Heterogeneity and pleiotropy tests showed no statistical significance (P > .05). Mediation analysis indicated that the abundance of the non-oxidative branch of the Pentose phosphate pathway and COVID-19 susceptibility was mediated by Sebacate (C10-DC) levels (mediation proportion of 15.8%), and the abundance of P goldsteinii and COVID-19 susceptibility was mediated by Acetoacetate levels (mediation proportion of 31.7%). The current MR study provides evidence supporting the causal relationships between several specific gut microbiotas and COVID-19 susceptibility, as well as potential mediating blood metabolites. Our findings warrant further validation through larger epidemiological studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.